Corcept Therapeutics

Corcept Therapeutics Inc. is a California based pharmaceutical company.

Areas of focus

• The company is engaged in the discovery, development and commercialization of drugs for the treatment of many metabolic, psychiatric and oncologic disorders.
• Corcept Therapeutics is focused on the adverse effects of excess cortisol, studying new compounds that may mitigate those effects.
• Its executive team is headed by CEO, president and director Joseph K. Belanoff, MD, and by chief medical officer Robert S. Fishman, MD.

Main products

• Korlym Mifepristone

In the pipeline

The following products are in the various stages of research by the company. Endocrinology

• Relacorilant for Endogenous Cushing syndrome, Hypercortisolism associated with cortisol-secreting adrenal adenoma or hyperplasia
• Miricorilant for Antipsychotic-induced weight gain (GRATITUDE), (GRATITUDE II) NASH

Oncology

• Relacorilant with Nab-paclitaxel FOR Ovarian cancer]]
• Exicorilant with Enzalutamide for Castration-resistant prostate cancer
• Mifepristone with Enzalutamide for Castration-resistant prostate cancer
• Mifepristone with Nab-paclitaxel for Metastatic GR-positive triple-negative breast cancer
• Mifepristone with Pembrolizumab for Metastatic HER2-negative breast cancer
• Relacorilant with Enzalutamide for Castration-resistant prostate cancer
• Relacorilant with Pembrolizumab for Adrenocortical cancer with glucocorticoid excess

Neurology CORT113176 for Amyotrophic lateral sclerosis (ALS)

Addiction Mifepristone with Behavioral Therapy for Alcohol use disorder

Ophthalmology Mifepristone for Central serous chorioretinopathy

Psychiatry CORT1082975 for Post-traumatic stress disorder (PTSD)

External links

• Company website

This article is a stub. You can help WikiMD by registering to expand it. Editing is available only to registered and verified users. WikiMD is a comprehensive, free health & wellness encyclopedia.